A randomized, double-blind, placebo-controlled trial of vitamin C iontophoresis in melasma

Dermatology

Volumn 206, Issue 4, 2003, Pages 316-320

  Huh, Chang Hun ^a   Seo, Koo Il ^b   Park, Je Young ^a   Lim, Jeong Gu ^a   Eun, Hee Chul ^a   Park, Kyung Chan ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Modelo Clinic   (South Korea)

Author keywords

Ascorbic acid; Chloasma; Iontophoresis; Magnesium L ascorbyl 2 phosphate; Melasma; Vitamin C

Indexed keywords

ASCORBIC ACID; PLACEBO; WATER;

ADULT; ARTICLE; BURNING SENSATION; CHLOASMA; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG PENETRATION; DRUG SOLUTION; ELECTRIC SHOCK; ERYTHEMA; FACE; FEMALE; HUMAN; IONTOPHORESIS; LUMINANCE; PARAMETER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN PIGMENTATION; XEROSIS;

ADULT; ANTIOXIDANTS; ASCORBIC ACID; COMPUTER GRAPHICS; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IONTOPHORESIS; MELANOSIS; MIDDLE AGED; NEUROCUTANEOUS SYNDROMES; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0038316424     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069943     Document Type: Article

References (14)

1. Lerner AB, Fitzpatrick TB: Biochemistry of melanin formation. Physiol Rev 1950;30:91-126.
2. Ros JR, Rodriguez-Lopes JN, Garcia-Canovas F: Effect of L-ascorbic acid on the monophelase activity of tyrosinase. Biochem J 1993;295:309-312.
3. Nomura H, Ishiguro T, Morimoto S: Studies on L-ascorbic acid derivatives. II. L-Ascorbic acid and 3-phosphate and 3-pyrophosphate. Chem Pharm Bull (Tokyo) 1989;17:381-386.
4. Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M, Murata T, Ohnuma T, Quigley J, Dorsky A, Bucks D, Blanock K: Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 1996;34:29-33.
5. Westerhof W: CIE Colorimetry; in Serup J, Jemec GBE (eds): Handbook of Noninvasive Methods and the Skin. Boca Raton, CRC Press, 1995, pp 385-397.
6. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y: Hypomelanoses and hypermelanoses; in Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (eds): Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 1999, pp 996-997.
7. Jimbow K, Minamitsuji Y: Topical therapies for melasma and disorders of hyperpigmentation. Dermatol Ther 2001;14:35-45.
8. Grimes PE: Melasma: Etiologic and therapeutic considerations. Arch Dermatol 1995;131:1453-1457.
9. Piamphongsant T: Treatment of melasma: A review with personal experience. Int J Dermatol 1998;37:897-903.
10. Lee SH, Choi EH, Feingold KR, Jiang S, Ahn SK: Iontophoresis itself on hairless mouse skin induces the loss of the epidermal calcium gradient without skin barrier impairment. J Invest Dermatol 1998;111:39-43.
11. Green PG, Flanagan M, Shroot B, Guy RH: Iontophoretic drug delivery; in Walkers KA, Hadgraft J (eds): Pharmaceutical Skin Penetration Enhancement. New York, Dekker, 1993, pp 311-333.
12. Chien YW, Siddiqui O, Shi WM, Lelawongs P, Liu JC: Direct current iontophoretic transdermal delivery of peptide and protein drugs. J Pharm Sci 1989;78:376-384.
13. Grimmes S: Pathways of ionic flow through human skin in vivo. Acta Derm Venereol (Stockh) 1984;64:93-98.
14. Suzuki H: Skin lightening with iontophoresis of L-ascorbic acid-2-phosphate (in Japanese). J Jpn Soc Aesthet Plast Surg 1998;20:46-67.